Clofibrate disposition in renal failure and acute and chronic liver disease

No abstract is available for this paper.

• Publication year

  1979

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  1979-06-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00558438PMID 456406
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clofibrate kinetics after single and multiple doses

  1978cited by this paper
• Control of clofibrate toxicity in uremic hypertriglyceridemia

  1977cited by this paper
• Untoward effects of clofibrate in hemodialyzed patients.

  1977cited by this paper
• Clofibrate in hemodialyzed patients.

  1977cited by this paper
• Normal disposition of oxazepam in acute viral hepatitis and cirrhosis.

  1976cited by this paper
• Delivery of di-2-ethylhexyl phthalate to patients during hemodialysis.

  1976cited by this paper
• A rapid gas chromatographic method for the determination of chlorophenoxyisobutyric acid in plasma and urine.

  1976cited by this paper
• Clofibrate-induced muscle damage in patients with chronic renal failure.

  1975cited by this paper
• Lack of Effect of Cholestyramine on the Pharmacokinetics of Clofibrate in Man

  1975cited by this paper
• Pharmacokinetics of drugs in patients with the nephrotic syndrome.

  1975cited by this paper
• Uremia and cardiovascular mortality.

  1974cited by this paper
• Letter: Effect of plasma protein binding on elimination of warfarin.

  1974cited by this paper
• INFLUENCE OF FREE FATTY ACID CONCENTRATION ON DRUG BINDING TO PLASMA ALBUMIN *

  1973cited by this paper
• Clofibrate for prevention of myocardial infarction.

  1973cited by this paper
• Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia.

  1972cited by this paper
• Clofibrate-induced acute muscular syndrome.

  1972cited by this paper
• The effect of clofibrate on serum and faecal lipids.

  1972cited by this paper
• Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia.

  1972cited by this paper
• Trial of Clofibrate in the Treatment of Ischaemic Heart Disease: FIVE-YEAR STUDY BY A GROUP OF PHYSICIANS OF THE NEWCASTLE UPON TYNE REGION*

  1971cited by this paper
• Time integral of drug concentration in the central (plasma) compartment.

  1970cited by this paper
• On the mechanism of action of atromid-S on triglyceride transport in man.

  1970cited by this paper
• Clofibrate, Serum Enzymes, and Muscle Pain

  1970cited by this paper
• Long‐Term Effects of Clofibrate (Atromid‐S) on Serum Lipids in Man

  1969cited by this paper
• Changes in the blood coagulation system associated with septicemia.

  1968cited by this paper
• LONG-TERM HEMODIALYSIS

  1968cited by this paper
• Uremic lipemia: an unrecognized abnormality in triglyceride synthesis and removal.

  1968cited by this paper
• Acute muscular syndrome associated with administration of clofibrate.

  1968cited by this paper
• PASSIVE IMMUNIZATION AGAINST TETANUS: SOME OBSERVATIONS ON THE USE AND REACTIVITY OF HETEROLOGOUS ANTITOXINS.

  1965cited by this paper
• THE EFFECT OF CHLOROPHENOXYISOBUTYRIC ACID AND ETHINYL ESTRADIOL ON CHOLESTEROL TURNOVER.

  1965cited by this paper
• Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate.

  1962cited by this paper
• EXPERIMENTAL EVALUATION OF AN ORALLY ACTIVE COMBINATION OF ANDROSTERONE WITH ETHYL CHLOROPHENOXYISOBUTYRATE

  1962cited by this paper

• Pharmacokinetics and Bioequivalence of Cefixime in Healthy Male and Female Volunteers

  2015cites this paper
• Renal Disposition of Drugs and Translation to Dosing Strategies

  2013cites this paper
• Influence of renal function on the pharmacokinetics of diacerein after a single oral dose

  2010cites this paper
• Acyl glucuronides: the good, the bad and the ugly.

  2010cites this paper
• 15 DRUG-PROTEIN BINDING IN LIVER DISEASE AND IN PATIENTS WITH HYPOALBUMINEMIA

  2009cites this paper
• Evaluation of Recombinant Cytochrome P450 Enzymes as an in Vitro System for Metabolic Clearance Predictions

  2009cites this paper
• Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.

  2008cites this paper
• UNIVERSITATIS UPSALIENSIS UPPSALA 2008 Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 71 Safety and Efficacy Modelling in Anti-Diabetic Drug Development

  2008cites this paper
• CHAPTER 98 – Disposition and Dose Requirements of Drugs in Renal Insufficiency

  2008cites this paper
• DRUG MILK TO SERUM RATIO PREDICTION AND ONTOGENY OF CYP3A CLEARANCE PATHWAY AS A MODEL OF DRUG EXPOSURE IN THE DEVELOPING RAT

  2007cites this paper
• Glucuronidation in therapeutic drug monitoring.

  2005cites this paper
• Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport

  2005cites this paper
• Pharmacokinetics of bendazac-lysine and 5-hydroxybendazac in patients with renal insufficiency

  2004cites this paper
• Metabolism of amitriptyline in patients with chronic renal failure

  2004cites this paper
• Acyl glucuronide reactivity in perspective: biological consequences.

  2003cites this paper
• Acyl Glucuronide Drug Metabolites: Toxicological and Analytical Implications

  2003cites this paper
• Renal handling of drugs and xenobiotics

  2003cites this paper
• Determination of mycophenolic acid and its phenol glucuronide metabolite in human plasma and urine by high-performance liquid chromatography.

  2001cites this paper
• Clinical Pharmacokinetics of Diacerein

  1998cites this paper
• Enzyme-linked immunosorbent assay for TA-2005-glucuronide in human plasma.

  1998cites this paper
• Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

  1997cites this paper
• The role of beta-glucuronidase in drug disposition and drug targeting in humans.

  1997cites this paper
• Drug metabolism in liver disease: implications for therapeutic drug monitoring.

  1996cites this paper
• Influence of renal function on the pharmacokinetics of diacerein after a single oral dose

  1993cites this paper
• Glucuronidation of Drugs

  1992cites this paper
• Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?

  1992cites this paper
• Microsomal liver function declines steadily after kidney grafting: a three to five year follow-up.

  1992cites this paper
• Drug glucuronidation in humans.

  1991cites this paper
• In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins.

  1991cites this paper
• Pharmacokinetic studies with the lipid-regulating agent beclobrate: enantiospecific assay for beclobric acid using a new fluorescent chiral coupling component (S-FLOPA).

  1991cites this paper
• Effect of esterase inhibition on the disposition of zomepirac glucuronide and its covalent binding to plasma proteins in the guinea pig.

  1990cites this paper
• Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

  1990cites this paper
• Prescribing for patients with liver disease.

  1989cites this paper
• Impaired liver function in stable renal allograft recipients

  1989cites this paper
• Effects of fibrates on serum lipids and atherosclerosis.

  1988cites this paper
• Guide to Drug Dosage in Hepatic Disease

  1988cites this paper
• Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study.

  1987cites this paper
• Clearance approaches in pharmacology.

  1987cites this paper
• Binding of drugs to sera of patients with renal disease and liver disease.

  1987cites this paper
• Morphine Pharmacokinetics in Renal Failure

  1987cites this paper
• Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man.

  1985cites this paper
• Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation.

  1985cites this paper
• Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs.

  1984cites this paper
• [Pharmacokinetic mechanisms of drug interactions. 3: Interaction mechanisms during distribution].

  1984cites this paper
• Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle.

  1984cites this paper
• Reduced elimination of ketoprofen in the elderly is not necessarily due to impaired glucuronidation.

  1984cites this paper
• Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man.

  1984cites this paper
• Alteration of Drug-Protein Binding in Renal Disease

  1984cites this paper
• Single‐dose ceftriaxone kinetics in liver insufficiency

  1984cites this paper
• Clofibrate-induced muscular syndrome. Case report with ultrastructural findings and review of the literature.

  1984cites this paper
• Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle.

  1983cites this paper
• [Dose adaptation of drugs for liver patients using a simple risk classification].

  1983cites this paper
• Glucuronidation and disposition of drug glucuronides in patients with renal failure. A review.

  1982cites this paper
• Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure.

  1982cites this paper
• Probenecid‐clofibrate interaction

  1981cites this paper
• Drug metabolites in renal failure: pharmacokinetic and clinical implications.

  1981cites this paper
• Hepatic Disease and Drug Pharmacokinetics

  1980cites this paper
• Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure

  1980cites this paper
• Metabolic disposition of antihyperlipidemic agents in man and laboratory animals.

  1980cites this paper
• [Clofibrate pharmacokinetics in chronic renal failure (author's transl)].

  1980cites this paper
• [Prescription of drugs in liver diseases].

  1980cites this paper